Particularly, the latter, the GLP-1 receptor agonists, either alone or in various combinations, are so powerful that treatment allows more than 2/3 of type 2 diabetes patients to reach glycemic targets
It is gradually increased over several weeks to the target dose
In some states, GLP-1s are available for weight management if strict clinical criteria are met while in other states coverage remains restricted to diabetes treatment only
Access this article Similar content being viewed by others References Gold MS, Kobeissy FH, Wang KK, Merlo LJ, Bruijnzeel AW, Krasnova IN, Cadet JL (2009) Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates
( PMID: 15767025 ) Wang JY, French LE, Shear NH, Amiri A, Alavi A (2018) Drug-induced pyoderma gangrenosum: a review